tradingkey.logo

Precigen Inc

PGEN
View Detailed Chart

3.800USD

-0.020-0.52%
Close 09/18, 16:00ETQuotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM

Precigen Inc

3.800

-0.020-0.52%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.52%

5 Days

-6.86%

1 Month

+29.25%

6 Months

+113.48%

Year to Date

+239.29%

1 Year

+281.14%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
100 / 175
Overall Ranking
257 / 4723
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
8.250
Target Price
+112.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
Undervalued
The company’s latest PE is -9.18, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 229.52M shares, decreasing 0.34% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.07M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.55.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEODr. Helen Sabzevari, Ph.D.
Websitehttps://precigen.com/
KeyAI